ONCOZ — Oncozenge AB Share News
0.000.00%
Last trade - 00:00- SEK89.74m
- SEK96.49m
- SEK2.66m
Brief: OncoZenge Says Positive Stability Results For BupiZenge
Brief: Oncozenge Q4 Operating Loss SEK 9.7 Mln
Brief: Oncozenge Receives Investment Capital From Yangtian Bio-Pharmaceutical
Brief: OncoZenge Enters Into Convertible Loan Agreement with Linc
Brief: OncoZenge Lacks Liquidity, Cites Investor Payment Delay
Brief: Oncozenge, Molteni Expand Partnership
Brief: Oncozenge Q3 Operating Loss SEK 3.5 Mln
Brief: OncoZenge Enters Into Collaboration With UCLA For Patient Engagement Study On Bupizenge
Brief: Oncozenge Q2 Operating Result Down To SEK -2,605 Thousand
Brief: Oncozenge Signs Amendment With Molteni Farmaceutici
Brief: Oncozenge Receives Investment Capital From Yangtian Bio-Pharmaceutical
Brief: Oncozenge Enters Into Convertible Loan Agreement With Linc AB
Brief: Oncozenge Q1 Net Sales Up At Of 2,713 Tsek
Brief: Oncozenge And Yangtian Pharma Enter Into Amendment To Investment Agreement
Brief: Oncozenge Enters Licensing Agreement With Avernus Pharma
Brief: Oncozenge Receives Initial Milestone Payment From Molteni Farmaceutici
Brief: Oncozenge Partners With Molteni Farmaceutici
Brief: Oncozenge Q4 Operating Loss Narrows To SEK 2.5 Mln
Brief: Oncozenge Enters Into SEK 30.2 Mln Investment Agreement With Strategic Investor Sichuan Yangtian Bio-Pharmaceutical